American Journal of Medical Quality

Dr. David B. Nash and Healthmap Solutions Team Up to Improve Kidney Health

Retrieved on: 
Mercredi, juillet 12, 2023
Health administration, University, Health policy, Population health, Population Health Management, Vassar College, Senior advisor, MBA, Medicine, Acos, Wharton School of the University of Pennsylvania, American Journal, MD, Patient, Widener University Commonwealth Law School, Kidney, Jefferson College, Dentistry, Health, Book, American Journal of Medical Quality, Nursing, HealthMap, Economics

TAMPA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- David B. Nash, MD, MBA, widely considered as the pioneer of population health management, is teaming up with kidney population health management company Healthmap Solutions, Inc. (Healthmap) in a Senior Advisor capacity.

Key Points: 
  • TAMPA, Fla., July 12, 2023 (GLOBE NEWSWIRE) -- David B. Nash, MD, MBA, widely considered as the pioneer of population health management, is teaming up with kidney population health management company Healthmap Solutions, Inc. (Healthmap) in a Senior Advisor capacity.
  • Dr. Nash will focus on strategy and program innovations for Healthmap’s national kidney health management program to benefit health plans, healthcare providers, and kidney patients.
  • “We are excited to have a visionary of David Nash’s caliber supporting the Healthmap team,” said Healthmap CEO Eric Reimer.
  • “David was talking about population health long before it was called population health, and today he has a keen understanding of where medicine, technology, and economics converge.”

Dr. David B. Nash Joins HealthTrackRx Strategic Advisory Board

Retrieved on: 
Mardi, avril 25, 2023
MedPage Today, Central Waqf Council, Population Health Management, Commission, Infection, JCPH, MBA, Commission on the Accreditation of Healthcare Management Education, COVID, Geisinger Commonwealth School of Medicine, Organization, American Journal, Publication, MD, Patient, Population health, Modern Healthcare, Healthcare in the United States, Humana, Accreditation, Jefferson College, Health, Book, PCR, American Journal of Medical Quality, Pharmaceutical industry, Nursing

DENTON, Texas, April 25, 2023 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced that David B. Nash, MD, MBA, the Founding Dean Emeritus at the Jefferson College of Population Health (JCPH), has joined its Strategic Advisory Board. A board-certified internist, Dr. Nash is internationally recognized for his work in public accountability for health outcomes, physician leadership development, and quality-of-care improvement.

Key Points: 
  • DENTON, Texas, April 25, 2023 /PRNewswire/ -- HealthTrackRx, the nation's premier molecular diagnostic testing laboratory, today announced that David B. Nash, MD, MBA, the Founding Dean Emeritus at the Jefferson College of Population Health (JCPH), has joined its Strategic Advisory Board.
  • A board-certified internist, Dr. Nash is internationally recognized for his work in public accountability for health outcomes, physician leadership development, and quality-of-care improvement.
  • "HealthTrackRx is transforming the way providers diagnose and treat infections," said Dr. Nash.
  • I am thrilled to join HealthTrackRx in developing clinical innovations that will get people healthier faster."

Diabetes Patients See Significant Benefit from Value-Based, Total Care Model, According to New Data from agilon health

Retrieved on: 
Mardi, janvier 24, 2023
Seniors, Hospitals, Diabetes, Clinical Trials, Health Insurance, Biotechnology, Managed Care, Pharmaceutical, Consumer, Health, Medicaid, MUA, Physician, Kidney failure, Star, Total care, Stroke, Patient, NYSE, American Journal of Medical Quality, Medicare, Splenic infarction, Paratriathlon, Mua people, Risk, FFS, Glycated hemoglobin, Health equity, Death, CMS, Centers for Medicare & Medicaid Services, Healthcare shortage area, MA, MD, Pharmaceutical industry

agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, has released new data examining the impact of its full-risk, Total Care Model (agilon model) among Medicare Advantage (MA) patients with diabetes.

Key Points: 
  • agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, has released new data examining the impact of its full-risk, Total Care Model (agilon model) among Medicare Advantage (MA) patients with diabetes.
  • The analysis additionally found that these benefits extend to patients with diabetes who receive care within the agilon model and live in Medically Underserved Areas (MUAs).
  • “These data underscore agilon’s mission to create a healthcare system that works better for both primary care physicians and senior patients,” said Steve Sell, chief executive officer, agilon health.
  • The analysis also found that the agilon model is effectively reducing the financial burden of diabetes care for both patients and the healthcare system.

Allevant Shares 10 Year Experience and Launches "Project Swing Bed on the MENDS®"

Retrieved on: 
Jeudi, septembre 22, 2022
Traction, Safety, Algorithm, WI, Medicare, Mayo Clinic Health System, MSN, Organizational culture, Virus, Learning, Hypertension, Patient, Physician, Exercise, Request for information, Critical Access Hospital, Transitional care, RN, Radiology, Life expectancy, Assistant, National Rural Health Association, Conditional sentence, Happy Human, Sleep, Growth, Obesity, COVID, EDS, Doctor of Philosophy, Mindfulness, American Journal of Medical Quality, Select Medical, Medical director, Culture, Hospital, Hope, Risk, Quality, Population, Senior, Operation, Diabetes, Length of stay, Cancer, Tobacco, Hobby, Transition, Health, American Journal, Nursing home, LLC, Mayo, Program, MS, CAH, ICU, Mayo Clinic, Failure, Bed, Medicine, Pharmaceutical industry, Nutrition

MECHANICSBURG, Pa., Sept. 22, 2022 /PRNewswire/ -- On February 1st, 2023, Allevant, developed by Mayo Clinic and Select Medical, is launching the first cohort of "Project Swing Bed on the MENDS®," a Critical Access Hospital (CAH) Shared Learning Collaborative. Participating CAHs will have access to Allevant staff, tools and resources to maximize their Swing Bed program and begin to implement MENDS®, a wellness program for healthcare staff and post-acute patients. 

Key Points: 
  • Allevant, developed by Mayo Clinic and Select Medical, is launching the first cohort of Project Swing Bed on the MENDS
    "Critical Access Hospitals can provide post-acute recovery via Transitional Care/Swing Bed better than virtually anyone else.
  • The results of the Mayo program initiated and led by Dr. Lindsay led to the launch of Allevant approximately 10 years ago.
  • He provides the example of the tertiary hospital in Eau Claire, WI where Dr. Lindsay first launched two Wisconsin Swing Bed programs.
  • If you have interest in participating in the first cohort of Project Swing Bed on the MENDS, contact Jordan Tenenbaum to learn more today.

Novel Study Demonstrates the Hospital-Wide Impact of the Steripath® Initial Specimen Diversion Device® on Blood Culture Contamination Rates and Sepsis Testing Accuracy at WVU Medicine - United Hospital Center

Retrieved on: 
Mercredi, avril 6, 2022
ISDT, Magnolia, Laboratory, Blood culture, Infection, Invention, Nursing, Patent, Clinical, Intravenous therapy, Multimedia, Patient, American Journal, WVU Medicine, Quality, Procedure, University Health System, Hospital, CEO, American Journal of Medical Quality, Emergency, Sepsis, Goal, Vancomycin, Intellectual property, CLSI, Clinical and Laboratory Standards Institute, FDA, MedStar Washington Hospital Center, Collection, Pharmaceutical industry, Medical device

SEATTLE, April 6, 2022 /PRNewswire/ -- Magnolia Medical Technologies, Inc., inventors of Steripath®, the only FDA 510(k)-cleared device platform indicated to reduce blood culture contamination for sepsis testing accuracy,1 today announced the publication of results from a study performed by United Hospital Center, a member of the West Virginia University Health System, clinically evaluating the impact of Steripath in reducing false-positive blood culture results throughout the hospital.

Key Points: 
  • The WVU Medicine leadership have prioritized a strategic initiative to reduce blood culture contamination system-wide, which includes an assessment of the impact of Steripath.
  • Magnolia Medical invented and patented the Initial Specimen Diversion Technique (ISDT) and Device (ISDD) for blood culture collection and contamination prevention.
  • Initial Specimen Diversion Device reduces blood culture contamination and vancomycin use in academic medical center.
  • Getting to zero: impact of a device to reduce blood culture contamination and false-positive central line-associated blood stream infections.

DECISIO Reveals New Leadership and Closes Series B Funding Round

Retrieved on: 
Lundi, mars 28, 2022
Trustee, Risk, Health, United States Department of Defense, Internal medicine, Leadership, Cigna, Retirement, Army of the United States, Multimedia, Board, Board of directors, American Board of Commissioners for Foreign Missions, Department of Defence, American Board of Internal Medicine, Organizational founder, CEO, Director, United States Army, TRICARE, American Journal of Medical Quality, LLC, Rosalind Franklin University of Medicine and Science, Tricare, American College, Workflow, Military Health System, Cerner, Solution, Department, Education, Fatigue, Hematology, Patient, Length of stay, Management, Medicine

Dr. Granger is currently President and CEO of The 5Ps, LLC, a healthcare, education, and leadership consulting organization.

Key Points: 
  • Dr. Granger is currently President and CEO of The 5Ps, LLC, a healthcare, education, and leadership consulting organization.
  • "Dr. Granger joining our board provides enormous value and validation for our company moving forward," said Dr. John Holcomb, Co-CEO and Cofounder of DECISIO.
  • "His expertise and leadership in the healthcare industry is a welcome addition to our esteemed group of Board of Directors''.
  • DECISIO is also announcing the official closure of its $18.5million Series B funding round in February 2022, bringing the total funds raised to date at $31.5 million.

David Nash MD to Join Genomind’s Scientific Advisory Board

Retrieved on: 
Mardi, novembre 9, 2021
Data Management, Health, Technology, Genetics, Software, Pharmaceutical, Biotechnology, Culture, Population, Safety, University, Drug, American Health, American Association, Coronavirus Scientific Advisory Board (Turkey), American Journal of Medical Quality, Population Health Management, Jefferson College, MD, Economics, Health policy, MBA, Gene, Pharmacogenomics, Logic, Accountable care organization, Joint Commission, Health administration, Dentistry, Software, SAB, Wendell Pritchett, Approximation error, American Journal, Thomas Jefferson University, Wharton School of the University of Pennsylvania, American Association of Clinical Endocrinologists, FACP, AAPL, Wellness, Penn, Population health, Vassar College, Phi Beta Kappa, Management, Pharmaceutical industry

Genomind , a leading precision healthcare company, has named David Nash, MD, MBA the newest member of its Scientific Advisory Board (SAB).

Key Points: 
  • Genomind , a leading precision healthcare company, has named David Nash, MD, MBA the newest member of its Scientific Advisory Board (SAB).
  • Dr. Nash is a principal faculty member for quality-of-care programming for the American Association for Physician Leadership (AAPL).
  • I am privileged to join an amazing group of nationally prominent experts on the Genomind Scientific Advisory Board, said Dr. Nash.
  • Population health refers to the distribution of health outcomes, resources, and equity within a population, said David Krause, MD, FACP, Co-CEO of Genomind.